Domestic gene sequencing equipment enterprise Hua Da Zhizhong landing in the science and technology innovation board rose over 22% of the market value exceeding 40 billion

Cover reporter Cai Shiqi

On September 9, 2022, Shenzhen Huada Intelligent Manufacturing Technology Co., Ltd. (referred to as "Hua Da Zhizao") officially landed on the Shanghai Stock Exchange Science and Technology Board with a securities code "688114". In the early morning, Huada Intelligence's stock price opened 107 yuan/share, an increase of 22.34%, and the market value exceeded 40 billion yuan.

Huada Zhizheng's online live online live broadcast ceremony adopted the "cloud knocking gong" mode and invited 13 guests to independently developed by the company and was known as the "Super Life Computer" ultra -high -throughput gene sequencing instrument - DNBSEQ-T7 participated in the ceremony of "Naruton".

Wang Jian, chairman of Huada Intelligent Manufacturing, said at the listing ceremony: "I believe that the first profit of Hua Da's intelligent manufacturing will definitely become a core hardcore technology support to answer major scientific issues such as the old and death, and the growth of all things. The industry prospects are infinitely bright. "

The new product of domestic small and medium -sized sequencers is open to the world for open reservations

On the day of listing, Huada Zhifa also announced its new sequencer DNBSEQ-G99.

According to reports, this gene sequencer is one of the fastest -speed models in the global equivalent sequencer. It is particularly suitable for targeted gene sequences and small genome sequences. The data output speed and high quality. The starting place of DNBSEQ-G99 is China. At present, many early users have launched trials and the trial data performance is excellent. This model will be open to reservations for users in overseas countries and regions since 2023.

For a long time, some foreign companies have been monopolizing the production of gene sequencers and forming a strict protection system. There are long time gaps in the field of domestic sequences. In 2013, Huada Group acquired Complete Genomics and set up a sequencing R & D team to seek to get rid of the dilemma of being "stuck" through independent research and development.

In 2016, Hua Dazhi was established. After several years of introduction, digestion, absorption, and re -innovation, Huada Intelligent Manufacturing has formed the three major business segments covering the gene sequencer business, laboratory automation business, and new businesses. As a technical -driven enterprise, Huada Zhifa has the ability to independently develop and mass -produce clinical sequencers, and the two high -end manufacturers of Illumina and thermo Fisher have a total of over 90%of the global market share, occupying the upstream of the gene sequencing industry chain chain market.

The revenue of the two major business sectors of gene sequencing and laboratory automation continues to grow

In recent years, the main business performance of Huada Intelligence has grown rapidly, but relevant persons have said that the company has also continued to expand business boundaries and enhance scale effects in the past two years. From the perspective of the business layout of Huada Intelligence, gene sequencing and laboratory automation are its two major business sectors.

From 2019 to 2021, the revenue of the two major business sectors has increased significantly. The revenue of the gene sequencing instrument business is 1.01 billion yuan, 615 million yuan, and 1.276 billion yuan, respectively, accounting for 92.44%, 22.34%, and 32.76, respectively. %; The revenue of the laboratory automation business was 58.973 million yuan, 2.062 billion yuan, and 2.193 billion yuan, respectively, accounting for 5.45%, 74.87%, and 56.27%, respectively.

From 2019 to 2021, the revenue of the new business sector of Huada Intelligence made 22.8259 million yuan, 766.702 million yuan, and 427.808 million yuan, respectively, which is expected to become a new profit growth point.

Thanks to the expansion of market channels and the expansion of product application scenarios, the revenue of non -epidemics of Huada Intelligence has also achieved rapid growth. In 2020 and 2021, the company's income from the new crown epidemic reached 795 million yuan and 1.584 billion yuan, accounting for 28.59%and 40.33%of operating income, respectively.

At the industry's prospects, gene sequencing instruments, as the upstream industry of high -tech barriers. In the past few years, the global gene sequencer and consumable markets have maintained double -digit growth. According to the "China Gene Sequencing Industry Market Prospective and Investment Strategic Planning Report", the global gene sequencing market size will reach US $ 34.1 billion in 2025, with a compound growth rate of 18%in five years.

- END -